Non-Traditional Therapies Could Fill Vital Mental Health Needs
FN Media Group Presents Microsmallcap.com Market Commentary
New York, NY – March 2, 2021 – Non-traditional therapies are coming a long way from their stigmatized roots. Rising rates of serious mental health issues and unreliability of traditional mental health treatments have spurred research into treatment forms utilizing once stigmatized and criminalized drugs. The results have been promising enough that the pharmaceutical industry around therapeutic MDMA, ketamine, psilocybin, and other psychoactive substances is taking shape and gaining momentum. Non-traditional therapies are gaining government regulatory approval and, in some cases, even breakthrough therapy designations, and the companies moving this revolution forward like Numinus Wellness Inc. (TSXV:NUMI) (OTCPK:LKYSF), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceuticals (NYSE:TAK), Optimi Health (CSE:OPTI), and Tryp Therapeutics (CSE:TRYP) (OTCPK:TRYPF) are finding huge opportunity here.
Numinus Wellness Advances MDMA-Assisted Therapy
Integrated mental health company Numinus Wellness Inc. (TSXV:NUMI) (OTCPK:LKYSF) is one of the companies working to advance innovative treatments like psychedelic-assisted psychotherapy into safe, evidence-based, accessible solutions. Through its Numinus Health segment, the company delivers innovative treatments to address physical, mental, and emotional health, through clinics and virtual services, while Numinus R&D conducts implementation science, and Numinus Bioscience serves as the company’s applied research and IP development lab.
In partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation, Numinus is conducting a single-arm, open-label, compassionate access trial for MDMA-assisted therapy for treatment of patients with post-traumatic stress disorder. On February 17, the company announced that the trial has made significant progress, successfully transitioning to the pre-implementation stage at Numinus’s Vancouver clinic.
“We are excited to share an update on the progress of our MDMA compassionate access trial with the full recognition that existing therapies for PTSD are inadequate,” Numinus CEO Payton Nyquvest said in the company’s release. “At Numinus, we are pleased to help foster a promising regulatory landscape that will contribute to a better understanding that psychedelic-assisted psychotherapies are a viable, safe, and necessary avenue for expanding existing treatment options. We look forward to continued collaboration with MAPS PBC and will work together to provide those experiencing PTSD with more treatment options.”
On February 8, Numinus completed the previously announced acquisition of Mindspace Psychology Services Inc. The Montreal-based Mindspace is an industry leading full-service mental health clinic staffed by a team of PhD-level psychotherapists. Mindspace launched Psychedelic Harm Reduction and Integration programming in 2019.
“Adding Mindspace to the Numinus platform will provide strong synergies for both companies,” Dr. Devon Christie, Medical Director at Numinus and a MAPS-trained therapist for the delivery of MDMA-assisted psychotherapy, said of the December 15 announcement of the acquisition. “The companies have similar values and complementary strengths, which make this a strong corporate and cultural fit. We are also proud to grow our presence nationally through this announcement.”
Non-Traditional Therapies Make Major Breakthroughs
In response to a worsening mental health crisis and the difficulty of treating common mental health issues with traditional therapies, innovative life sciences companies are conducting vital research and development. Tryp Therapeutics (CSE:TRYP) (OTCPK:TRYPF) is currently running a research program on psilocybin for neuropsychiatric disorders while the company also works on developing a synthetic form of psilocybin for clinical use. On February 16, Tryp announced that the company had begun the process of manufacturing a demonstration batch of 200g non-GMP psilocybin doses as part of a series of steps towards formulating and developing a cGMP psilocybin therapeutic treatment.
Also working with psilocybin, Optimi Health (CSE:OPTI) is preparing an evolving product family of functional mushroom-based formulations to help transform and “optimize” human development. Recently, the company announced that it had received a Research Exemption from Health Canada, which authorizes its proposed research and development protocols for both psilocybin and psilocin.
Other companies are looking to ketamine and ketamine-like drugs as a promising treatment for treatment-resistant depression. Japanese pharmaceutical company Takeda Pharmaceuticals (NYSE:TAK) has been overseeing clinical trials on a synthetic ketamine alternative that the company says replicates ketamine’s antidepressant action with fewer risks.
Spravato, a ketamine-derived nasal spray for treatment-resistant depression developed and marketed by multinational pharmaceutical and CPGs giant Johnson & Johnson (NYSE:JNJ) received authorization from the European Commission on February 8. The drug had already received approval from the FDA in 2019, becoming the first materially new treatment for depression to hit the market in decades.
Companies like Numinus Wellness that are researching and developing non-traditional therapies like MDMA-assisted therapy are helping to bring forward a new era of mental health treatment.
Disclaimer: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Numinus Wellness
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
FN Media Group, LLC